As First-Line Treatment in Adults with Advanced or Unresectable Hepatocellular CarcinomaTOKYO, Aug 23, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known ...
More From BioPortfolio on "Eisai: European Commission Grants Marketing Authorization for LENVIMA (Lenvatinib)"